GE HealthCare (GEHC) grants CFO stock options and RSUs awards

Rhea-AI Filing Summary

SACCARO JAMES reported acquisition or exercise transactions in this Form 4 filing.

GE HealthCare Technologies Inc. reported that Chief Financial Officer James Saccaro received equity awards on March 2, 2026. He was granted 32,797 employee stock options and 12,475 restricted stock units, each at a price of $0.00 per unit.

The restricted stock units vest 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. The stock options become exercisable on the same 33%/33%/34% schedule over those dates. Following the stock award, Saccaro directly holds 84,161 shares of common stock and 32,797 options.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider SACCARO JAMES

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	32,797	$0.00	--
Grant/Award	Common Stock, par value $0.01 per share	12,475	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 32,797 shares (Direct); Common Stock, par value $0.01 per share — 84,161 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare Technologies Inc. ("GE HealthCare") common stock. Award of restricted stock units with respect to GE HealthCare common stock, of which 33% will vest on September 2, 2027, 33% will vest on September 2, 2028, and 34% will vest on September 2, 2029. Award of an employee stock option with respect to GE HealthCare common stock, of which 33% will become exercisable on September 2, 2027, 33% will become exercisable on September 2, 2028, and 34% will become exercisable on September 2, 2029.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SACCARO JAMES

(Last) (First) (Middle)

500 W. MONROE STREET

(Street)

CHICAGO IL 60661

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GE HealthCare Technologies Inc. [ GEHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.01 per share	03/02/2026		A		12,475(1)(2)	A	$0	84,161	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$80.16	03/02/2026		A		32,797		(3)	03/02/2036	Common Stock, par value $0.01 per share	32,797	$0(3)	32,797	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare Technologies Inc. ("GE HealthCare") common stock.

2. Award of restricted stock units with respect to GE HealthCare common stock, of which 33% will vest on September 2, 2027, 33% will vest on September 2, 2028, and 34% will vest on September 2, 2029.

3. Award of an employee stock option with respect to GE HealthCare common stock, of which 33% will become exercisable on September 2, 2027, 33% will become exercisable on September 2, 2028, and 34% will become exercisable on September 2, 2029.

Remarks:

	/s/ Frank R. Jimenez, General Counsel and Corporate Secretary, as attorney-in-fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider equity awards did GEHC CFO James Saccaro receive?

GE HealthCare’s CFO James Saccaro received equity awards on March 2, 2026, consisting of stock options and restricted stock units. The filing reports 32,797 employee stock options and 12,475 restricted stock units, both granted at a price of $0.00 per unit.

How many stock options were granted to GEHC’s CFO in this Form 4?

The Form 4 shows an award of 32,797 employee stock options to GE HealthCare’s CFO. These options are tied to GE HealthCare common stock and become exercisable in three tranches: 33% in 2027, 33% in 2028, and 34% in 2029, on specified September 2 dates.

What restricted stock unit grant did GEHC disclose for its CFO?

GE HealthCare disclosed a grant of 12,475 restricted stock units to its CFO. Each unit represents the right to receive one share of GE HealthCare common stock at settlement, with vesting of 33% in 2027, 33% in 2028, and 34% in 2029 on stated September 2 dates.

What is the vesting schedule for GEHC CFO James Saccaro’s awards?

Both the restricted stock units and employee stock options follow the same vesting pattern. According to the filing, 33% vest or become exercisable on September 2, 2027, another 33% on September 2, 2028, and the remaining 34% on September 2, 2029.

How many GEHC shares does the CFO own after these reported grants?

After the March 2, 2026 grant of 12,475 common shares reported as an award, the CFO’s direct common stock holdings total 84,161 shares. Separately, he holds 32,797 employee stock options, which follow the specified three-year exercisability schedule beginning in 2027.

Were these GEHC insider transactions open-market buys or awards?

The transactions are classified as awards rather than open-market purchases. The Form 4 uses transaction code “A” for grant, award, or other acquisition, with a price of $0.00 per share for both the 32,797 stock options and 12,475 restricted stock units granted to the CFO.